Alternatives to Insilico Medicine

Owkin's K Pro is an autonomous AI scientist agent for biopharma R&D, turning multimodal patient data into drug discovery and clinical trial

Iktos pairs generative AI with robotic lab automation to compress small-molecule drug discovery.

Recursion runs AI drug discovery as a lab-in-the-loop engine — automated cellular imaging at scale feeding generative chemistry and a clinical pipeline.

Evotec is a life-science partner running AI-assisted drug discovery and Just–Evotec Biologics manufacturing.

Nimbus Therapeutics designs highly selective small-molecule drugs for oncology, immunology, and metabolic disease.

Physics-based molecular simulation with AI for drug discovery and materials design.

Causal AI drug discovery pairing 20+ petabytes of cellular data with human genetics to find true disease targets

BenevolentAI applies a decade-built biomedical knowledge graph to drug target discovery and repurposing for biopharma R&D teams.

Open-source, self-hosted AI research assistant for drug discovery — molecular property prediction, virtual screening and PK/PD modeling on your own hardware.

Recursion OS pairs automated wet labs with AI models for AI drug discovery at up to 2 million weekly experiments.

AI drug discovery engine pairing 2M weekly automated lab experiments with a 50+ PB proprietary dataset.

AI-CRISPR target discovery platform pairing AlgenCRISPR gene modulation with the AlgenBrain foundation model for causal immunology and

AI patient identification for clinical trials: HealthKey scans your EHR daily and emails your team trial-eligible patients.

Clinician-centered clinical trial matching that notifies your patients when a local, medically relevant study exists.

Nanograb designs peptide-LNP targeting systems with biophysics-informed AI so genetic medicines reach a chosen cell type instead of the liver.

Isomorphic Labs uses AI drug discovery models to design novel molecules and predict how candidate drugs will perform.

Renamed: Deep 6 AI was acquired by Tempus AI in March 2025 and its trial matching folded into Tempus.

Tempus pairs tumor DNA/RNA sequencing with AI precision oncology analytics to surface treatment and trial matches

PathAI's AISight Dx brings FDA-cleared digital pathology and AI biomarker algorithms to labs and biopharma trials.

SciSpace BioMed Agent runs multi-omics, variant prioritization, and drug repurposing analysis from plain-language biomedical prompts.

AI evidence assembly and quantitative modeling for clinical pharmacology — MBMA databases, Project Optimus dose work, exposure-response

Project-based AI biopharma team that delivers decision-grade research, analysis, and computational design in 3–5 days.

AI-native pharma company using autonomous agents to find new uses for existing drugs and predict patient drug response

PicnicAI turns patient health records into clinical research data and real-world evidence.

Frekils runs end-to-end real-world evidence studies on your clinical data, with AI writing the statistical code and your patient records never leaving your

BioStack Platforms supplies structured clinical datasets and RL environments for healthcare AI teams.

AI and computational bionanotechnology R&D partnership that designs field-ready molecular diagnostics for emerging biological threats in days, not 12+ months.

Silico is Goodfire's interpretability agent for understanding and debugging the internals of your AI models.

Atomwise APEX Protocol screens 10 billion compounds in under 30 seconds for small-molecule drug discovery

Oncology real-world evidence platform combining high-fidelity patient data with AI-assisted cancer research insights.